TY  - JOUR
AU  - Rašić, Jelena
AU  - Ivanović, Nevena
AU  - Anđelković, Marija
AU  - Nedeljković, Ivana
AU  - Nikolić, Ivan
AU  - Stojanović, Sava
AU  - Ristić-Medić, Danijela
AU  - Takić, Marija
AU  - Đorđević, Brižta
AU  - Dikić, Nenad
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3972
AB  - The aim of this study was to determine the ergogenic effects and the safety profile of a one-component higenamine supplement in female recreational athletes. Twelve recreational female basketball players (age 29–41 years, oxygen consumption (VO2max) > 30 ml⋅kg–1⋅min–1, with training > 5 h wk–1) were randomized either to the higenamine group, or to the placebo group for 3 weeks. In order to determine ergogenic effects and safety profile of higenamine administration, we assessed the following variables before and after 3 weeks of supplementation: anthropometric parameters, resting metabolic rate (RMR), exercise testing variables, serum free fatty acids (FFAs), blood pressure, enzyme activity, urea, lipid profile, and complete blood count. There were no differences between groups in anthropometric parameters, including basal metabolic rate (BMR), RMR and body fat [p = 0.706 (Cohen’s d 0.223), p = 0.169 (Cohen’s d 0.857), and p = 0.223 (Cohen’s d 0.750), respectively], FFAs [0.43 ± 0.03 vs. 0.54 ± 0.23, p = 0.206 (Cohen’s d 0.540)], neither significant differences in cardiopulmonary parameters after the intervention period. Furthermore, all measured outcome variables in the safety assessment were not significant, with values remaining stable during the intervention period for participants in both groups. This is the first study to document the effects and the safety profile of higenamine-based dietary supplements at a specified dose in female recreational athletes. Our data indicate that 21-day of supplementation with 75 mg higenamine would not result in improving cardiopulmonary exercise fitness and weight loss in female recreational athletes. Moreover, supplementation with 75 mg higenamine is safe and well-tolerated in younger recreational female athletes.
PB  - Frontiers Media S.A.
T2  - Frontiers in Psychology
T1  - Influence of Higenamine on Exercise Performance of Recreational Female Athletes: A Randomized Double-Blinded Placebo-Controlled Trial
VL  - 12
DO  - 10.3389/fpsyg.2021.633110
ER  - 

@article{
author = "Rašić, Jelena and Ivanović, Nevena and Anđelković, Marija and Nedeljković, Ivana and Nikolić, Ivan and Stojanović, Sava and Ristić-Medić, Danijela and Takić, Marija and Đorđević, Brižta and Dikić, Nenad",
year = "2021",
abstract = "The aim of this study was to determine the ergogenic effects and the safety profile of a one-component higenamine supplement in female recreational athletes. Twelve recreational female basketball players (age 29–41 years, oxygen consumption (VO2max) > 30 ml⋅kg–1⋅min–1, with training > 5 h wk–1) were randomized either to the higenamine group, or to the placebo group for 3 weeks. In order to determine ergogenic effects and safety profile of higenamine administration, we assessed the following variables before and after 3 weeks of supplementation: anthropometric parameters, resting metabolic rate (RMR), exercise testing variables, serum free fatty acids (FFAs), blood pressure, enzyme activity, urea, lipid profile, and complete blood count. There were no differences between groups in anthropometric parameters, including basal metabolic rate (BMR), RMR and body fat [p = 0.706 (Cohen’s d 0.223), p = 0.169 (Cohen’s d 0.857), and p = 0.223 (Cohen’s d 0.750), respectively], FFAs [0.43 ± 0.03 vs. 0.54 ± 0.23, p = 0.206 (Cohen’s d 0.540)], neither significant differences in cardiopulmonary parameters after the intervention period. Furthermore, all measured outcome variables in the safety assessment were not significant, with values remaining stable during the intervention period for participants in both groups. This is the first study to document the effects and the safety profile of higenamine-based dietary supplements at a specified dose in female recreational athletes. Our data indicate that 21-day of supplementation with 75 mg higenamine would not result in improving cardiopulmonary exercise fitness and weight loss in female recreational athletes. Moreover, supplementation with 75 mg higenamine is safe and well-tolerated in younger recreational female athletes.",
publisher = "Frontiers Media S.A.",
journal = "Frontiers in Psychology",
title = "Influence of Higenamine on Exercise Performance of Recreational Female Athletes: A Randomized Double-Blinded Placebo-Controlled Trial",
volume = "12",
doi = "10.3389/fpsyg.2021.633110"
}

Rašić, J., Ivanović, N., Anđelković, M., Nedeljković, I., Nikolić, I., Stojanović, S., Ristić-Medić, D., Takić, M., Đorđević, B.,& Dikić, N.. (2021). Influence of Higenamine on Exercise Performance of Recreational Female Athletes: A Randomized Double-Blinded Placebo-Controlled Trial. in Frontiers in Psychology
Frontiers Media S.A.., 12.
https://doi.org/10.3389/fpsyg.2021.633110

Rašić J, Ivanović N, Anđelković M, Nedeljković I, Nikolić I, Stojanović S, Ristić-Medić D, Takić M, Đorđević B, Dikić N. Influence of Higenamine on Exercise Performance of Recreational Female Athletes: A Randomized Double-Blinded Placebo-Controlled Trial. in Frontiers in Psychology. 2021;12.
doi:10.3389/fpsyg.2021.633110 .

Rašić, Jelena, Ivanović, Nevena, Anđelković, Marija, Nedeljković, Ivana, Nikolić, Ivan, Stojanović, Sava, Ristić-Medić, Danijela, Takić, Marija, Đorđević, Brižta, Dikić, Nenad, "Influence of Higenamine on Exercise Performance of Recreational Female Athletes: A Randomized Double-Blinded Placebo-Controlled Trial" in Frontiers in Psychology, 12 (2021),
https://doi.org/10.3389/fpsyg.2021.633110 . .

TY  - CONF
AU  - Marinković, Danica
AU  - Minić, Rajna
AU  - Dikić, Nenad
AU  - Anđelković, Marija
AU  - Vukašinović-Vesić, Milica
AU  - Kostić-Vučićević, Marija
AU  - Stojmenović, Tamara
AU  - Nikolić, Ivan
AU  - Đorđević, Brižita
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2637
PB  - Lippincott Williams & Wilkins, Philadelphia
C3  - Journal of Clinical Gastroenterology
T1  - The Effect of Lactobacillus Helveticus L10 Supplementation on Respiratory Infections and Mucosal Immunity in Elite Athletes
VL  - 50
IS  - Supplement 2
SP  - S227
EP  - S228
DO  - 10.1097/MCG.0000000000000691
ER  - 

@conference{
author = "Marinković, Danica and Minić, Rajna and Dikić, Nenad and Anđelković, Marija and Vukašinović-Vesić, Milica and Kostić-Vučićević, Marija and Stojmenović, Tamara and Nikolić, Ivan and Đorđević, Brižita",
year = "2016",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Journal of Clinical Gastroenterology",
title = "The Effect of Lactobacillus Helveticus L10 Supplementation on Respiratory Infections and Mucosal Immunity in Elite Athletes",
volume = "50",
number = "Supplement 2",
pages = "S227-S228",
doi = "10.1097/MCG.0000000000000691"
}

Marinković, D., Minić, R., Dikić, N., Anđelković, M., Vukašinović-Vesić, M., Kostić-Vučićević, M., Stojmenović, T., Nikolić, I.,& Đorđević, B.. (2016). The Effect of Lactobacillus Helveticus L10 Supplementation on Respiratory Infections and Mucosal Immunity in Elite Athletes. in Journal of Clinical Gastroenterology
Lippincott Williams & Wilkins, Philadelphia., 50(Supplement 2), S227-S228.
https://doi.org/10.1097/MCG.0000000000000691

Marinković D, Minić R, Dikić N, Anđelković M, Vukašinović-Vesić M, Kostić-Vučićević M, Stojmenović T, Nikolić I, Đorđević B. The Effect of Lactobacillus Helveticus L10 Supplementation on Respiratory Infections and Mucosal Immunity in Elite Athletes. in Journal of Clinical Gastroenterology. 2016;50(Supplement 2):S227-S228.
doi:10.1097/MCG.0000000000000691 .

Marinković, Danica, Minić, Rajna, Dikić, Nenad, Anđelković, Marija, Vukašinović-Vesić, Milica, Kostić-Vučićević, Marija, Stojmenović, Tamara, Nikolić, Ivan, Đorđević, Brižita, "The Effect of Lactobacillus Helveticus L10 Supplementation on Respiratory Infections and Mucosal Immunity in Elite Athletes" in Journal of Clinical Gastroenterology, 50, no. Supplement 2 (2016):S227-S228,
https://doi.org/10.1097/MCG.0000000000000691 . .

TY  - JOUR
AU  - Michalickova, Danica
AU  - Minić, Rajna
AU  - Dikić, Nenad
AU  - Anđelković, Marija
AU  - Kostić-Vučićević, Marija
AU  - Stojmenović, Tamara
AU  - Nikolić, Ivan
AU  - Đorđević, Brižita
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3441
AB  - A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severity and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes.
PB  - Canadian Science Publishing, Nrc Research Press, Ottawa
T2  - Applied Physiology Nutrition and Metabolism
T1  - Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial
VL  - 41
IS  - 7
SP  - 782
EP  - 789
DO  - 10.1139/apnm-2015-0541
ER  - 

@article{
author = "Michalickova, Danica and Minić, Rajna and Dikić, Nenad and Anđelković, Marija and Kostić-Vučićević, Marija and Stojmenović, Tamara and Nikolić, Ivan and Đorđević, Brižita",
year = "2016",
abstract = "A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severity and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes.",
publisher = "Canadian Science Publishing, Nrc Research Press, Ottawa",
journal = "Applied Physiology Nutrition and Metabolism",
title = "Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial",
volume = "41",
number = "7",
pages = "782-789",
doi = "10.1139/apnm-2015-0541"
}

Michalickova, D., Minić, R., Dikić, N., Anđelković, M., Kostić-Vučićević, M., Stojmenović, T., Nikolić, I.,& Đorđević, B.. (2016). Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. in Applied Physiology Nutrition and Metabolism
Canadian Science Publishing, Nrc Research Press, Ottawa., 41(7), 782-789.
https://doi.org/10.1139/apnm-2015-0541

Michalickova D, Minić R, Dikić N, Anđelković M, Kostić-Vučićević M, Stojmenović T, Nikolić I, Đorđević B. Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. in Applied Physiology Nutrition and Metabolism. 2016;41(7):782-789.
doi:10.1139/apnm-2015-0541 .

Michalickova, Danica, Minić, Rajna, Dikić, Nenad, Anđelković, Marija, Kostić-Vučićević, Marija, Stojmenović, Tamara, Nikolić, Ivan, Đorđević, Brižita, "Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial" in Applied Physiology Nutrition and Metabolism, 41, no. 7 (2016):782-789,
https://doi.org/10.1139/apnm-2015-0541 . .

TY  - JOUR
AU  - Michalickova, Danica
AU  - Minić, Rajna
AU  - Dikić, Nenad
AU  - Anđelković, Marija
AU  - Kostić-Vučićević, Marija
AU  - Stojmenović, Tamara
AU  - Nikolić, Ivan
AU  - Đorđević, Brižita
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2753
AB  - A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severity and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes.
PB  - Canadian Science Publishing, Nrc Research Press, Ottawa
T2  - Applied Physiology Nutrition and Metabolism
T1  - Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial
VL  - 41
IS  - 7
SP  - 782
EP  - 789
DO  - 10.1139/apnm-2015-0541
ER  - 

@article{
author = "Michalickova, Danica and Minić, Rajna and Dikić, Nenad and Anđelković, Marija and Kostić-Vučićević, Marija and Stojmenović, Tamara and Nikolić, Ivan and Đorđević, Brižita",
year = "2016",
abstract = "A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severity and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes.",
publisher = "Canadian Science Publishing, Nrc Research Press, Ottawa",
journal = "Applied Physiology Nutrition and Metabolism",
title = "Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial",
volume = "41",
number = "7",
pages = "782-789",
doi = "10.1139/apnm-2015-0541"
}

Michalickova, D., Minić, R., Dikić, N., Anđelković, M., Kostić-Vučićević, M., Stojmenović, T., Nikolić, I.,& Đorđević, B.. (2016). Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. in Applied Physiology Nutrition and Metabolism
Canadian Science Publishing, Nrc Research Press, Ottawa., 41(7), 782-789.
https://doi.org/10.1139/apnm-2015-0541

Michalickova D, Minić R, Dikić N, Anđelković M, Kostić-Vučićević M, Stojmenović T, Nikolić I, Đorđević B. Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. in Applied Physiology Nutrition and Metabolism. 2016;41(7):782-789.
doi:10.1139/apnm-2015-0541 .

Michalickova, Danica, Minić, Rajna, Dikić, Nenad, Anđelković, Marija, Kostić-Vučićević, Marija, Stojmenović, Tamara, Nikolić, Ivan, Đorđević, Brižita, "Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial" in Applied Physiology Nutrition and Metabolism, 41, no. 7 (2016):782-789,
https://doi.org/10.1139/apnm-2015-0541 . .